The United States (US) FDA is joining Australia in the battle
of the bulge by approving the laparoscopic banding use in obese
adults with a Body Mass Index (BMI)* as low as 30 and one
Australia was the first in the Asia-Pacific region to recently approve the gastric band for use in people with a BMI over 35 or a BMI greater than 30 with at least one serious, obesity-related condition.
For the first time, adults across the whole obesity spectrum who have failed conventional weight loss measures (diet, exercise and medication) can access this clinically effective, long-term, weight loss option.
The FDA has approved the laparoscopic adjustable gastric banding (LAGB) procedure for people with a BMI greater than 35, or people with a BMI greater than 30 and at least one serious, obesity-related condition, and who are unable to lose weight through conventional weight loss methods.
Landmark Australian research contributed to the FDA’s approval of the gastric band for use in adults within the lower limits of obesity. A world-first study, conducted at the Centre for Obesity Research and Education (CORE) at Monash University, compared the effectiveness of LAGB to non-surgical treatment (diet, exercise and medication) in obese adults with a BMI between 30 and 35. The research found that LAGB resulted in a loss of 87 per cent in excess body weight, compared to 21 per cent with non-surgical treatment; a greater reduction in obesity-related health conditions for LAGB; greater improvements in quality of life across all measures with LAGB. (9)
A second Australian study also conducted at CORE, that formed part of the FDA submission, revealed that gastric banding surgery is five times more likely to reverse type 2 diabetes than simple lifestyle changes.(10) The study revealed 20 per cent of average body weight loss with LAGB compared to 1.4 per cent average body weight loss with conventional diabetes care; an 80 per cent improvement to normal limit blood sugar (glucose) levels with LAGB, compared to 20 per cent with conventional diabetes care; a greater reduction in the use of diabetes medication with LAGB and a greater reduction in associated health conditions, including use of blood pressure and lipid lowering medications. (10)
Dr. Stephen Wilkinson – Tasmania Antiobesity Surgery Centre
Ph: 03 6214 3063
03 6214 3066
Fax: 03 6214 3064
Ph: 03 6432 6000
Fax: 03 6432 6099